Wednesday, January 29, 2014

Amgen analyst call report available

I am running a bit behind, but just finished:

Amgen (AMGN) analyst conference call report

My general impression was positive. Moving the needle at Amgen is a big deal, but they have a big pipeline, with a lot of data from Phase III trials coming out this year. That should mean revenue ramps in 2015. Lots of Phase II and Phase I trials underway as well.

For a long-term investor it looks like a no-brainer. However, I don't currently hold AMGN. It is one of several biotechnology stocks on my short list for my next investment round, some time after earnings season ends.

No comments:

Post a Comment